EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

The Value of Chemokine and Chemokine Receptors in Diagnosis, Prognosis, and Immunotherapy of Hepatocellular Carcinoma

Zhengyi Wu, Liang Sun, Yongkang Xu iD, He Huang, Zhipeng Wu, Bingbing Qiu, Jinlong Yan iD, Xiangbao Yin

Cancer Management and Research · 2024-05 · Volume 16 · 403-420

DOI: 10.2147/cmar.s450959 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Management and Research, 2024-05. Verfasst von Zhengyi Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hepatobiliary Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, People's Republic of…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chemokines and chemokine receptors (CCRs) are involved in a variety of anti-tumour and pro-tumour immune processes in vivo, such as angiogenesis, metastasis, proliferation and invasiveness, and influence patient prognosis and response to therapy.

Methods

CCRs differentially expressed in HCC and associated with prognosis were extracted from TCGA and GEO databases, and the obtained CCRs were then used to construct signature genes, and the signature gene were selected for expression validation as well as functional experiments to explore the role of CCRs in the treatment and prognosis of HCC.

Results

We constructed a prognostic model including five CCRs (CCL20, CCL23, CCR3, CCR10, and CXCR3) and validated the expression of signature genes. The model's risk score is an independent prognostic factor for HCC. We have also developed prognostic model nomograms for clinical use. In addition, we validated that CCR3 expression is associated with poor prognosis in HCC, and the proliferation and migration ability of HCC cells was significantly inhibited after interfering with the expression of CCR3 in MHCC-LM3. We also looked at differences in pathway enrichment, immune infiltration and immune checkpoints. Finally, we found that risk scores were also correlated with drug sensitivity, the high-risk group had a better sensitivity to sorafenib.

Conclusion

The CCRs-related gene signature may better assess HCC prognosis and response to immunotherapy and tyrosine kinase inhibitors such as sorafenib in HCC, providing prospective solutions for diagnosis and treatment.

Schlagwörter

Stichwörter der Autor:innen

chemokinechemokine receptorshepatocellular carcinomaprognosissignature

Autor:innen und Institutionen

  • Hepatobiliary Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, People's Republic of China.

ORCID-Profile: Yongkang Xu, Jinlong Yan

Zitieren

APA

Wu, Z., Sun, L., Xu, Y., Huang, H., Wu, Z., Qiu, B., Yan, J., & Yin, X. (2024). The Value of Chemokine and Chemokine Receptors in Diagnosis, Prognosis, and Immunotherapy of Hepatocellular Carcinoma. Cancer Management and Research, Volume 16, 403-420. https://doi.org/10.2147/cmar.s450959

Vancouver

Wu Z, Sun L, Xu Y, Huang H, Wu Z, Qiu B, et al. The Value of Chemokine and Chemokine Receptors in Diagnosis, Prognosis, and Immunotherapy of Hepatocellular Carcinoma. Cancer Management and Research. 2024;Volume 16:403-420. doi:10.2147/cmar.s450959

BibTeX
@article{Wu2024,
  author = {Wu, Zhengyi and Sun, Liang and Xu, Yongkang and Huang, He and Wu, Zhipeng and Qiu, Bingbing and Yan, Jinlong and Yin, Xiangbao},
  title = {The Value of Chemokine and Chemokine Receptors in Diagnosis, Prognosis, and Immunotherapy of Hepatocellular Carcinoma},
  journal = {Cancer Management and Research},
  year = {2024},
  volume = {Volume 16},
  pages = {403--420},
  doi = {10.2147/cmar.s450959}
}
Kostenlos starten →